Medical Aspects of Biological Warfare
Tularemia Chapter 11 TULAREMIA † ‡ MATTHEW J. HEPBURN, MD*; TODD M. KIJEK ; WENDY SAMMONS-JACKSON, PhD ; ARTHUR M. FRIEDLANDER, MD§; and ZYGMUNT F. DEMBEK, PhD, MS, MPH, LHD¥ INTRODUCTION INFECTIOUS AGENT THE CLINICAL DISEASE Epidemiology Pathogenesis Clinical Manifestations Diagnosis Treatment PROPHYLAXIS Postexposure Prophylaxis Vaccination With Live Vaccine Strain ISSUES FOR LABORATORY WORKERS USE OF TULAREMIA AS A BIOLOGICAL WEAPON SUMMARY *Colonel, MC, US Army; Program Manager, Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), 675 North Randolph Street, Room 08-140, Arlington, Virginia 22203-2114; formerly, Clinical Research Unit Lead, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland †Major, Medical Service Corps, US Army; PhD candidate and Chief, Molecular and Translational Sciences Department, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland 21702; formerly, Research Microbiologist, Bacteriology Division, US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland ‡Lieutenant Colonel, Medical Service Corps, US Army; Military Deputy, Science and Technology Department, US Army Medical Research and Materiel Command, 810 Schreider Street, Suite 103, Fort Detrick, Maryland 21702; formerly, Deputy Director, Military Infectious Diseases Research Program, Fort Detrick, Maryland §Colonel (Retired), Medical Corps, US Army; Senior Scientist, Bacteriology Division,
[Show full text]